Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

In a post hoc analysis of the LUX-Lung 3/6 trials, afatinib dose reduction, more likely occurring in patients who had higher afatinib plasma concentrations, led to decreases in incidence and severity of treatment-related adverse events without impacting treatment efficacy. Afatinib should be initiated at the approved dose of 40 mg/day; adjustments can then be used to optimize individual treatment.

from Cancer via ola Kala on Inoreader http://ift.tt/2c67NHw
via IFTTT